SCHEMBL14670621

SCHEMBL14670621

O=C1c2cc(Cl)ccc2-c2ccc3ccccc3c21

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DNMT1 P26358 1/20 0.64
▸ S100A4 P26447 2/20 0.58
▸ MEN1 O00255 2/20 0.48
▸ ALDH1A1 P00352 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ MAPT P10636 1/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ HSP90AA1 P07900 4/20 0.44
▸ HSP90AB1 P08238 3/20 0.43
▸ CES1 P23141 3/20 0.42
▸ CYP2A6 P11509 1/20 0.42
▸ USP8 P40818 1/20 0.42
▸ USP7 Q93009 1/20 0.42
▸ USP47 Q96K76 1/20 0.42
▸ CYP1A2 P05177 2/20 0.41
▸ CYP1B1 Q16678 1/20 0.41
▸ PAX8 Q06710 1/20 0.40
▸ APAF1 O14727 1/20 0.40
▸ IDO1 P14902 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19152440 0.87 S100A4 (0.53) DNMT1S100A4MEN1ALDH1A1KMT2A
SCHEMBL31106330 0.87 S100A4 (0.53) DNMT1S100A4MEN1ALDH1A1KMT2A
SCHEMBL22289446 0.83 DNMT1 (0.54) DNMT1S100A4MEN1ALDH1A1KMT2A
SCHEMBL31195807 0.83 DNMT1 (0.54) DNMT1S100A4MEN1ALDH1A1KMT2A
SCHEMBL16144670 0.82 DNMT1 (0.67) DNMT1MEN1ALDH1A1KMT2AMAPT
SCHEMBL2175783 0.82 DNMT1 (0.92) DNMT1S100A4MEN1ALDH1A1KMT2A
SCHEMBL30375875 0.82 DNMT1 (0.92) DNMT1S100A4MEN1ALDH1A1KMT2A
SCHEMBL29440308 0.82 DNMT1 (0.92) DNMT1S100A4MEN1ALDH1A1KMT2A
SCHEMBL19230419 0.82 DNMT1 (0.83) DNMT1MEN1ALDH1A1KMT2AMAPT
SCHEMBL7818661 0.81 DNMT1 (0.56) DNMT1S100A4MEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10283716-B2 Compound for organic electric element, organic electric element using the same, and electronic device comprising same DUK SAN NEOLUX CO., LTD. (KR) 2019-05-07 — — US disclosed
US-20180026187-A1 NOVEL COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT USING THE SAME, AND ELECTRONIC DEVICE COMPRISING SAME DUK SAN NEOLUX CO., LTD. (KR) 2018-01-25 — — US disclosed
US-20180026187-A1 NOVEL COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT USING THE SAME, AND ELECTRONIC DEVICE COMPRISING SAME DUK SAN NEOLUX CO., LTD. (KR) 2018-01-25 — — US disclosed
WO-2017123008-A1 ORGANIC LIGHT-EMITTING DEVICE, ORGANIC LIGHT-EMITTING DISPLAY DEVICE, AND COMPOUND FOR ORGANIC LIGHT-EMITTING DEVICE 덕산네오룩스 주식회사 2017-07-20 — — WO disclosed
WO-2017123008-A1 ORGANIC LIGHT-EMITTING DEVICE, ORGANIC LIGHT-EMITTING DISPLAY DEVICE, AND COMPOUND FOR ORGANIC LIGHT-EMITTING DEVICE 덕산네오룩스 주식회사 2017-07-20 — — WO disclosed
WO-2013015340-A1 2-ARYL HALIDE-1-NAPHTHALDEHYDE COMPOUND, METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING TRIARYLAMINE COMPOUND FROM SAID COMPOUND 東ソー株式会社 (JP) 2013-01-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180026187-A1 NOVEL COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT USING THE SAME, AND ELECTRONIC DEVICE COMPRISING SAME EBPL, OR51E2, EML4 DNMT1 340/4885S100A4 3206/4885MEN1 1483/4885
US-10283716-B2 Compound for organic electric element, organic electric element using the same, and electronic device comprising same EBPL, OR51E2, EML4 DNMT1 167/4885S100A4 3119/4885MEN1 1376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback